232 related articles for article (PubMed ID: 18756532)
1. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
Luo HY; Xu RH; Wang F; Qiu MZ; Li YH; Li FH; Zhou ZW; Chen XQ
Chemotherapy; 2010; 56(2):94-100. PubMed ID: 20357440
[TBL] [Abstract][Full Text] [Related]
3. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V; Raoul JL; Pignon JP; Bouché O; Blanc JF; Dahan L; Jouve JL; Dupouy N; Ducreux M;
Br J Cancer; 2007 Oct; 97(7):862-7. PubMed ID: 17876335
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Milella M; Gelibter A; Di Cosimo S; Bria E; Ruggeri EM; Carlini P; Malaguti P; Pellicciotta M; Terzoli E; Cognetti F
Cancer; 2004 Jul; 101(1):133-8. PubMed ID: 15221998
[TBL] [Abstract][Full Text] [Related]
8. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Gunnlaugsson A; Anderson H; Fernebro E; Kjellén E; Byström P; Berglund K; Ekelund M; Påhlman L; Holm T; Glimelius B; Johnsson A
Eur J Cancer; 2009 Mar; 45(5):807-13. PubMed ID: 19110416
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
[TBL] [Abstract][Full Text] [Related]
11. Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
Gunnlaugsson A; Anderson H; Lind P; Glimelius B; Johnsson A
Radiother Oncol; 2010 Jun; 95(3):292-7. PubMed ID: 20451275
[TBL] [Abstract][Full Text] [Related]
12. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Coskun U; Buyukberber S; Yaman E; Uner A; Er O; Ozkan M; Dikilitas M; Oguz M; Yildiz R; B DY; Kaya AO; Benekli M
Neoplasma; 2008; 55(1):65-70. PubMed ID: 18190244
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
López R; Méndez CM; Fernández MJ; Reinoso CR; Aldana GQ; Fernández MS; DE LA Cámara Gómez J; López MR; Vázquez MR; Folgar SC
Anticancer Res; 2013 Feb; 33(2):717-23. PubMed ID: 23393373
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
Zaniboni A; Aitini E; Barni S; Ferrari D; Cascinu S; Catalano V; Valmadre G; Ferrara D; Veltri E; Codignola C; Labianca R
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1641-5. PubMed ID: 22576338
[TBL] [Abstract][Full Text] [Related]
15. [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Shi SB; Ma TH; Tang XY; Li CH
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):301-4. PubMed ID: 23985261
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer.
Shi SB; Wang M; Niu ZX; Tang XY; Liu QY
Pancreatology; 2012; 12(6):475-9. PubMed ID: 23217281
[TBL] [Abstract][Full Text] [Related]
19. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Bayoglu IV; Varol U; Yildiz I; Muslu U; Alacacioglu A; Kucukzeybek Y; Akyol M; Demir L; Dirican A; Cokmert S; Yildiz Y; Karabulut B; Uslu R; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(17):7119-23. PubMed ID: 25227800
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
Møller AK; Pedersen KD; Abildgaard J; Petersen BL; Daugaard G
Acta Oncol; 2010 May; 49(4):431-5. PubMed ID: 20235750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]